The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AURA BIOSCIENCES INC | COM | 05153U107 | 37,542,666 | 3,039,892 | SH | SOLE | 1 | 3,039,892 | 0 | 0 | |
CENTESSA PHARMACEUTICALS PLC | SPONSORED ADS | 152309100 | 123,571,942 | 19,963,157 | SH | SOLE | 1 | 19,963,157 | 0 | 0 | |
PHATHOM PHARMACEUTICALS INC | COM | 71722W107 | 53,855,644 | 3,760,869 | SH | SOLE | 1 | 3,760,869 | 0 | 0 | |
MERUS N V | COM | N5749R100 | 42,128,000 | 1,600,000 | SH | SOLE | 1 | 1,600,000 | 0 | 0 | |
NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | N62509109 | 34,119,128 | 2,869,565 | SH | SOLE | 1 | 2,869,565 | 0 | 0 | |
VAXCYTE INC | COM | 92243G108 | 65,692,824 | 1,315,435 | SH | SOLE | 1 | 1,315,435 | 0 | 0 |